← SynDRA
TAK-960
SynDRA canonical compound SYN0037403 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | PLK1 |
|---|
| Mechanism of action | PLK inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- PLK1 INHIBITOR
- Serine/threonine-protein kinase PLK1 inhibitor
- PLK inhibitor
- PLK1 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP2C9
- CP3A7
- IFNB1
- KSYK
- NSD2
- NTM1A
- NTMT1
- PARP1
- SYK
Cross-references
Synonyms
- TAK960
- TAK 960
- CHEMBL2392545
- AK172385
- benzamide, 4-[(9-cyclopentyl-7,7-difluoro-6,7,8,9-tetrahydro-5-methyl-6-oxo-5h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-n-(1-methyl-4-piperidinyl)-
- 4-[(9-Cyclopentyl-7,7-Difluoro-5-Methyl-6-Oxo-6,7,8,9-Tetrahydro-5h-Pyrimido[4,5-B][1,4]diazepin-2-Yl)amino]-2-Fluoro-5-Methoxy-N-(1-Methylpiperidin-4-Yl)benzamide
- RefChem:187202
- PLK1 Inhibitor TAK-960
- Polo-like Kinase 1 Inhibitor TAK-960
- yl)benzamide
- C27H34F3N7O3
- MFCD22420821
- UNII-3831VFM1ZB
- orb1299985
- SCHEMBL1560793
- 5H,6H,7H,8H,9H-pyrimido[4,5-b][1,4]diazepin-2-
- SCHEMBL29361245
- SCHEMBL30047124
- EX-A382
- GLXC-05988
- HMS3753O13
- TAK-960?
- BDBM50435727
- NSC768072
- AKOS025290223
- CS-4412
- NSC-768072
- PB31224
- SB20412
- NCGC00387488-01
- NCGC00387488-02
- NCGC00387488-03
- AC-35770
- DA-47794
- FT104283
- HY-15160
- MS-30195
- T7200
- F861522
Look up TAK-960 in the interactive SynDRA portal →